[SCHEDULE 13G/A] Rigel Pharmaceuticals Inc. (New) SEC Filing
Armistice Capital, LLC and Steven Boyd filed a Schedule 13G/A reporting beneficial ownership of 1,600,000 shares of Rigel Pharmaceuticals, representing 8.92% of the outstanding common stock. The filing states these shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager and over which Armistice Capital and Mr. Boyd share voting and dispositive power.
The filing clarifies the Master Fund retains the economic right to proceeds or dividends while disclaiming direct beneficial ownership due to the investment management agreement. All reported share counts are based on 17,937,340 shares outstanding as of July 31, 2025, per the issuers SEC filing.
Armistice Capital, LLC e Steven Boyd hanno presentato un Schedule 13G/A segnalando la titolarit脿 beneficiaria di 1.600.000 azioni di Rigel Pharmaceuticals, pari al 8,92% del capitale sociale ordinario in circolazione. La comunicazione indica che tali azioni sono detenute direttamente da Armistice Capital Master Fund Ltd., per la quale Armistice Capital agisce come gestore degli investimenti e per le quali Armistice Capital e il sig. Boyd condividono i poteri di voto e di disposizione.
Il deposito precisa che il Master Fund conserva il diritto economico sui proventi o sui dividendi, pur rinunciando alla qualifica di beneficiario diretto a causa dell鈥檃ccordo di gestione degli investimenti. Tutte le cifre relative alle azioni si basano su 17.937.340 azioni in circolazione al 31 luglio 2025, secondo il deposito SEC dell鈥檈mittente.
Armistice Capital, LLC y Steven Boyd presentaron un Schedule 13G/A informando la propiedad beneficiaria de 1.600.000 acciones de Rigel Pharmaceuticals, lo que representa el 8,92% del capital social ordinario en circulaci贸n. La presentaci贸n indica que dichas acciones est谩n en posesi贸n directa de Armistice Capital Master Fund Ltd., para el cual Armistice Capital act煤a como gestor de inversiones y sobre las que Armistice Capital y el Sr. Boyd comparten el poder de voto y de disposici贸n.
El documento aclara que el Master Fund mantiene el derecho econ贸mico a los ingresos o dividendos, aunque renuncia a la condici贸n de beneficiario directo debido al acuerdo de gesti贸n de inversiones. Todos los recuentos de acciones reportados se basan en 17.937.340 acciones en circulaci贸n a fecha 31 de julio de 2025, seg煤n la presentaci贸n ante la SEC del emisor.
Armistice Capital, LLC鞕� Steven Boyd電� Rigel Pharmaceuticals鞚� 1,600,000欤�毳� 鞁れ鞝� 靻岇湢搿� 氤搓碃頃橂姅 Schedule 13G/A毳� 鞝滌稖頄堨溂氅�, 鞚措姅 氚滍枆欤检嫕鞚� 8.92%鞐� 頃措嫻頃╇媹雼�. 鞝滌稖靹滊電� 頃措嫻 欤检嫕鞚� Armistice Capital鞚� 韴瀽鞖挫毄靷靹� 甏�毽晿電� Armistice Capital Master Fund Ltd.臧� 歆侅爲 氤挫湢頃橁碃 鞛堨溂氅�, Armistice Capital瓿� Boyd 鞌皜 鞚橁舶甓� 氚� 觳橂秳甓岇潉 瓿奠湢頃滊嫟瓿� 氇呾嫓頃╇媹雼�.
靹滊電� 韴瀽鞖挫毄瓿勳暯鞙茧 鞚疙暣 Master Fund臧� 靾橃澋鞚措倶 氚半嫻鞐� 雽�頃� 瓴届牅鞝� 甓岆Μ電� 氤挫湢頃橂悩 歆侅爲鞝� 鞁れ鞝� 靻岇湢鞛愳瀯鞚� 攵�鞚疙暅雼り碃 靹る獏頃╇媹雼�. 氤搓碃霅� 氇摖 欤检嫕 靾橂姅 氚滍枆靷皜 SEC鞐� 鞝滌稖頃� 鞛愲鞐� 霐半ジ 2025雲� 7鞗� 31鞚� 旮办 齑� 17,937,340欤茧ゼ 旮办鞙茧 頃╇媹雼�.
Armistice Capital, LLC et Steven Boyd ont d茅pos茅 un Schedule 13G/A signalant la propri茅t茅 b茅n茅ficiaire de 1 600 000 actions de Rigel Pharmaceuticals, repr茅sentant 8,92% des actions ordinaires en circulation. Le d茅p么t indique que ces actions sont d茅tenues directement par Armistice Capital Master Fund Ltd., pour lequel Armistice Capital agit en tant que gestionnaire d'investissement et sur lesquelles Armistice Capital et M. Boyd partagent le pouvoir de vote et de disposition.
Le document pr茅cise que le Master Fund conserve le droit 茅conomique aux recettes ou dividendes tout en d茅clinant la qualit茅 de propri茅taire b茅n茅ficiaire directe en raison du contrat de gestion d'investissement. Tous les totaux d'actions rapport茅s se fondent sur 17 937 340 actions en circulation au 31 juillet 2025, selon le d茅p么t SEC de l'茅metteur.
Armistice Capital, LLC und Steven Boyd haben ein Schedule 13G/A eingereicht, in dem sie den wirtschaftlichen Besitz von 1.600.000 Aktien der Rigel Pharmaceuticals melden, was 8,92% des ausstehenden Stammkapitals entspricht. Die Einreichung gibt an, dass diese Aktien direkt von Armistice Capital Master Fund Ltd. gehalten werden, f眉r den Armistice Capital als Investmentmanager fungiert und 眉ber den Armistice Capital und Herr Boyd Stimm- und Verf眉gungsrechte teilen.
Die Meldung stellt klar, dass der Master Fund das wirtschaftliche Recht auf Ertr盲ge oder Dividenden beh盲lt, aber aufgrund des Investment-Management-Vertrags die direkte wirtschaftliche Eigent眉merschaft ablehnt. Alle angegebenen Aktienzahlen basieren auf 17.937.340 ausstehenden Aktien per 31. Juli 2025 laut der SEC-Einreichung des Emittenten.
- None.
- None.
Insights
TL;DR: Armistice Capital and Steven Boyd disclose an 8.92% stake (1.6M shares) in Rigel, a material passive ownership disclosure under Schedule 13G/A.
This Schedule 13G/A indicates a non-control, investment-manager-managed position where Armistice Capital exercises shared voting and dispositive power over 1,600,000 shares held by the Master Fund. The position equals 8.92% of the class based on 17,937,340 shares outstanding, which exceeds the 5% reporting threshold and is therefore material to holders and market observers. The filing emphasizes passive intent and ordinary-course acquisition consistent with Schedule 13G treatment.
TL;DR: Filing documents shared voting/dispositive authority via an investment manager relationship, with explicit disclaimer of direct Master Fund ownership.
The disclosure clarifies roles: Armistice Capital is the investment manager with voting and investment power; Steven Boyd, as managing member, is identified as a reporting person. The Master Fund retains economic rights to dividends and proceeds but disclaims beneficial ownership due to the management agreement. This delineation is important for governance transparency and for understanding who holds voting influence versus economic interest.
Armistice Capital, LLC e Steven Boyd hanno presentato un Schedule 13G/A segnalando la titolarit脿 beneficiaria di 1.600.000 azioni di Rigel Pharmaceuticals, pari al 8,92% del capitale sociale ordinario in circolazione. La comunicazione indica che tali azioni sono detenute direttamente da Armistice Capital Master Fund Ltd., per la quale Armistice Capital agisce come gestore degli investimenti e per le quali Armistice Capital e il sig. Boyd condividono i poteri di voto e di disposizione.
Il deposito precisa che il Master Fund conserva il diritto economico sui proventi o sui dividendi, pur rinunciando alla qualifica di beneficiario diretto a causa dell鈥檃ccordo di gestione degli investimenti. Tutte le cifre relative alle azioni si basano su 17.937.340 azioni in circolazione al 31 luglio 2025, secondo il deposito SEC dell鈥檈mittente.
Armistice Capital, LLC y Steven Boyd presentaron un Schedule 13G/A informando la propiedad beneficiaria de 1.600.000 acciones de Rigel Pharmaceuticals, lo que representa el 8,92% del capital social ordinario en circulaci贸n. La presentaci贸n indica que dichas acciones est谩n en posesi贸n directa de Armistice Capital Master Fund Ltd., para el cual Armistice Capital act煤a como gestor de inversiones y sobre las que Armistice Capital y el Sr. Boyd comparten el poder de voto y de disposici贸n.
El documento aclara que el Master Fund mantiene el derecho econ贸mico a los ingresos o dividendos, aunque renuncia a la condici贸n de beneficiario directo debido al acuerdo de gesti贸n de inversiones. Todos los recuentos de acciones reportados se basan en 17.937.340 acciones en circulaci贸n a fecha 31 de julio de 2025, seg煤n la presentaci贸n ante la SEC del emisor.
Armistice Capital, LLC鞕� Steven Boyd電� Rigel Pharmaceuticals鞚� 1,600,000欤�毳� 鞁れ鞝� 靻岇湢搿� 氤搓碃頃橂姅 Schedule 13G/A毳� 鞝滌稖頄堨溂氅�, 鞚措姅 氚滍枆欤检嫕鞚� 8.92%鞐� 頃措嫻頃╇媹雼�. 鞝滌稖靹滊電� 頃措嫻 欤检嫕鞚� Armistice Capital鞚� 韴瀽鞖挫毄靷靹� 甏�毽晿電� Armistice Capital Master Fund Ltd.臧� 歆侅爲 氤挫湢頃橁碃 鞛堨溂氅�, Armistice Capital瓿� Boyd 鞌皜 鞚橁舶甓� 氚� 觳橂秳甓岇潉 瓿奠湢頃滊嫟瓿� 氇呾嫓頃╇媹雼�.
靹滊電� 韴瀽鞖挫毄瓿勳暯鞙茧 鞚疙暣 Master Fund臧� 靾橃澋鞚措倶 氚半嫻鞐� 雽�頃� 瓴届牅鞝� 甓岆Μ電� 氤挫湢頃橂悩 歆侅爲鞝� 鞁れ鞝� 靻岇湢鞛愳瀯鞚� 攵�鞚疙暅雼り碃 靹る獏頃╇媹雼�. 氤搓碃霅� 氇摖 欤检嫕 靾橂姅 氚滍枆靷皜 SEC鞐� 鞝滌稖頃� 鞛愲鞐� 霐半ジ 2025雲� 7鞗� 31鞚� 旮办 齑� 17,937,340欤茧ゼ 旮办鞙茧 頃╇媹雼�.
Armistice Capital, LLC et Steven Boyd ont d茅pos茅 un Schedule 13G/A signalant la propri茅t茅 b茅n茅ficiaire de 1 600 000 actions de Rigel Pharmaceuticals, repr茅sentant 8,92% des actions ordinaires en circulation. Le d茅p么t indique que ces actions sont d茅tenues directement par Armistice Capital Master Fund Ltd., pour lequel Armistice Capital agit en tant que gestionnaire d'investissement et sur lesquelles Armistice Capital et M. Boyd partagent le pouvoir de vote et de disposition.
Le document pr茅cise que le Master Fund conserve le droit 茅conomique aux recettes ou dividendes tout en d茅clinant la qualit茅 de propri茅taire b茅n茅ficiaire directe en raison du contrat de gestion d'investissement. Tous les totaux d'actions rapport茅s se fondent sur 17 937 340 actions en circulation au 31 juillet 2025, selon le d茅p么t SEC de l'茅metteur.
Armistice Capital, LLC und Steven Boyd haben ein Schedule 13G/A eingereicht, in dem sie den wirtschaftlichen Besitz von 1.600.000 Aktien der Rigel Pharmaceuticals melden, was 8,92% des ausstehenden Stammkapitals entspricht. Die Einreichung gibt an, dass diese Aktien direkt von Armistice Capital Master Fund Ltd. gehalten werden, f眉r den Armistice Capital als Investmentmanager fungiert und 眉ber den Armistice Capital und Herr Boyd Stimm- und Verf眉gungsrechte teilen.
Die Meldung stellt klar, dass der Master Fund das wirtschaftliche Recht auf Ertr盲ge oder Dividenden beh盲lt, aber aufgrund des Investment-Management-Vertrags die direkte wirtschaftliche Eigent眉merschaft ablehnt. Alle angegebenen Aktienzahlen basieren auf 17.937.340 ausstehenden Aktien per 31. Juli 2025 laut der SEC-Einreichung des Emittenten.
